{"id":"doi:10.1038/s41598-017-13282-7","kind":"article","title":"Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms","authors":["Carhart-Harris RL","Roseman L","Bolstridge M","Demetriou L","Pannekoek JN","Wall MB","Tanner M","Kaelen M","McGonigle J","Murphy K","Leech R","Curran HV","Nutt DJ"],"author_count":13,"year":2017,"published":"2017-10-13","venue":"Scientific reports","cited_by":415,"doi":"10.1038/s41598-017-13282-7","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1038/s41598-017-13282-7","archive_url":"https://space-kitty.com/papers/doi:10.1038/s41598-017-13282-7","updated":null,"pmid":"29030624","pmcid":"PMC5640601","openalex_id":null,"pdf_url":"https://europepmc.org/articles/PMC5640601/pdf","abstract":"Psilocybin with psychological support is showing promise as a treatment model in psychiatry but its therapeutic mechanisms are poorly understood. Here, cerebral blood flow (CBF) and blood oxygen-level dependent (BOLD) resting-state functional connectivity (RSFC) were measured with functional magnetic resonance imaging (fMRI) before and after treatment with psilocybin (serotonin agonist) for treatment-resistant depression (TRD). Quality pre and post treatment fMRI data were collected from 16 of 19 patients. Decreased depressive symptoms were observed in all 19 patients at 1-week post-treatment and 47% met criteria for response at 5 weeks. Whole-brain analyses revealed post-treatment decreases in CBF in the temporal cortex, including the amygdala. Decreased amygdala CBF correlated with reduced depressive symptoms. Focusing on a priori selected circuitry for RSFC analyses, increased RSFC was observed within the default-mode network (DMN) post-treatment. Increased ventromedial prefrontal cortex-bilateral inferior lateral parietal cortex RSFC was predictive of treatment response at 5-weeks, as was decreased parahippocampal-prefrontal cortex RSFC. These data fill an important knowledge gap regarding the post-treatment brain effects of psilocybin, and are the first in depressed patients. The post-treatment brain changes are different to previously observed acute effects of psilocybin and other 'psychedelics' yet were related to clinical outcomes. A 'reset' therapeutic mechanism is proposed.","abstract_license":"CC-BY (article license as recorded by Europe PMC; abstract reproduced unmodified apart from markup removal)","license":"CC-BY","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":[],"details":null,"provenance":"europepmc","attribution":"Abstract of \"Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms\" by Carhart-Harris RL, Roseman L, Bolstridge M et al., https://doi.org/10.1038/s41598-017-13282-7, used under its Creative Commons Attribution license (CC-BY); markup removed, otherwise unmodified.","topics":[{"slug":"psychiatric-therapeutics","name":"Novel Psychiatric Therapeutics","domain_slug":"neuroscience"}],"cited_in_dossiers":[]}